Form 4: Eli Lilly Executive Jacob Van Naarden Reports Stock Transactions

Eli Lilly executive Jacob Van Naarden reported the acquisition and disposal of company stock and restricted stock units on February 12, 2024.

Summary

• Jacob Van Naarden, an Executive Vice President at Eli Lilly, reported transactions involving the company's common stock and restricted stock units.
• On February 12, 2024, Mr. Van Naarden acquired 2,369 shares of common stock at a price of $737.26 per share.
• He also disposed of 16,147 shares of common stock held indirectly through the Van Naarden Family Trust.
• Additionally, Mr. Van Naarden acquired 3,023 restricted stock units, each representing a contingent right to receive one share of Eli Lilly common stock, with an exercisable date of February 1, 2025.
• The reporting person disclaims beneficial ownership of the reported securities held by the Van Naarden Family Trust except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing of stock transactions by an executive, and does not indicate any positive or negative sentiment.

Industry Context

This is a routine SEC Form 4 filing, which is standard practice for corporate insiders reporting transactions in their company's stock. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• Form 4 filings are a standard requirement for all publicly traded companies in the United States.
• The transactions reported are typical for executives who receive stock-based compensation and may manage personal investment portfolios.
• The reporting of both acquisitions and disposals is common, reflecting the dynamic nature of executive stock holdings.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive stock ownership.
• The filing is a routine part of corporate governance and does not indicate any significant impact on stakeholders.

Key Dates

Keywords

stock transactions, insider trading, restricted stock units, executive compensation, common stock, Eli Lilly, LLY